Industry News

DARE-19 Phase III Collaboration between AstraZeneca, Saint Luke’s Mid America Heart Institute and George Clinical Shows Treatment’s Well-Established Safety Profile Was Consistent in Patients with COVID-19

Detailed results from the primary analysis of the DARE-19 Phase III trial assessing the potential of Farxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to treat patients hospitalized with COVID-19 who are at risk of developing serious complications showed that the trial did not achieve statistical significance for the two primary endpoints. However, there were […]

Read More

May 19th, 2021

Research underscores importance of early detection of anemia, high blood pressure, and diabetes during pregnancy

There is an urgent need to raise awareness among rural women and healthcare workers at all levels of the postpartum period and the long-term health of women with a history of hypertension and gestational diabetes mellitus (GDM). Early identification and counseling of women at high risk of cardiometabolic disorders through innovative community-level interventions may offer […]

Read More

June 6th, 2020

George Institute Study Shows Women More Likely Than Men to Survive Stroke but Have Poorer Recovery

Women are more likely to survive a stroke, but have a worse disability and poorer quality of life afterward compared to men, according to research published in the latest issue of Neurology®, the medical journal of the American Academy of Neurology.  The George Institute for Global Health researchers looked at sex differences in treatment and […]

Read More

March 13th, 2020

WHO Endorsement of Simpler Drug Treatment for Blood Pressure Will Improve Treatment Availability for 1 Billion People

George Clinical welcomes the addition of fixed dose combinations (FDCs) of blood pressure (BP) lowering drugs to the World Health Organization (WHO) Essential Medicines List (EML) in response to an application filed by Resolve to Save Lives (RTSL), an initiative of vital strategies, The George Institute and other partners. Adding FDCs of blood pressure lowering […]

Read More

July 31st, 2019

Big and Small Pharma Enjoy a Significant Opportunity to Leverage India for Trials

The Indian subcontinent deserves to be considered by pharmaceutical or biotech firms examining clinical trial locations, and veteran industry players may be surprised to learn India is already a leading destination for global clinical trials with significant growth taking place in the biotech sector.   Prime opportunities exist for all phases of clinical trials due to […]

Read More

July 17th, 2019

George Clinical Awarded Taiwanese Drug License

 SYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors.  The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]

Read More

May 14th, 2019

EPS International and George Clinical Form Strategic Partnership for the Asia-Pacific Region

Sydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]

Read More

April 24th, 2019

George Clinical Client Noxopharm Announces Chemotherapy Enhancement Program Expansion

Noxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]

Read More

April 20th, 2019

George Clinical Congratulates Parent Company The George Institute For Global Health For Securing $12 Million To Tackle Worlds Biggest Killers

[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock […]

Read More

February 12th, 2019

Taiwan’s Pragmatic Timelines Make it a ‘Top-Tier’ Country for MRCTs

George Clinical welcomes The Taiwan Food and Drug Administration’s (TFDA) recent clarified timelines for approval of a general Clinical Trial Authority (CTA) at 45 calendar days. The announcement, released by the TFDA in October, adds to the suite of attractive options to expedite clinical trial regulatory approval timelines in Taiwan. This includes the existing 15 […]

Read More

January 8th, 2019